A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Update Il y a 4 ans
Reference: NCT00162500

Woman and Man

  • | Country :
  • Israel
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Rationale: ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population. Purpose: The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).


Inclusion criteria

  • Multiple myeloma ,Tumors

Links